Xintela gets product patent in USA for chondrocyte-based products
Xintela today announces that the US Patent and Trademark Office (USPTO) has issued the company’s patent application on chondrocyte-based cell therapy products, with validity through 2039.
Xintela’s US patent, US 11, 725,188, protects the development and commercialization of chondrocyte-based products that are quality assured using the cell surface markers integrin α10β1 and integrin α11β1. The patent is valid until 2039. Xintela has previously received patents for quality assurance of isolated and expanded chondrocytes in several countries including the US and Japan and also a product patent in Japan.
“We are very pleased with this patent. It demonstrates how we continue to innovate to broaden the use of our integrin markers, in this case, for the development and commercialization of high quality chondrocyte products. In discussions with potential collaboration partners and licensees, we see that this patent can have great value, not least for the development of allogeneic (donated) chondrocyte products”, says Xintela’s CEO Evy Lundgren-Åkerlund.
Xintela has previously reported on the company’s analytical method for chondrocytes, XACT (Xintela Assay for Cell Therapy), which makes it possible to determine the quality and purity of isolated and cultured chondrocytes and develop high quality chondrocyte products for the repair of injured cartilage.